Evaluation of Elexacafor/Tezacaftor/Ivacaftor therapy after lung transplantation in Cystic Fibrosis: The Dutch National KOALA study
Background: Elexacaftor/Tezacaftor/Ivacaftor (ETI) for people with CF (PwCF) after lung transplantation (LTx) has been restrained due to uncertainties regarding efficacy and drug interactions. Given the persistence of extrapulmonary symptoms post-LTx, this prospective study aims to investigate the b...
Saved in:
Main Authors: | Johanna P. van Gemert, Bart Luijk, Merel E. Hellemons, Klara A. Visser, Carina.M.E. Hansen, Renske van der Meer, C. Tji Gan, Hester van der Vaart, Onno W. Akkerman, Willie N. Steenhuis, Marieke Verkleij, Harry G.M. Heijerman, Erik A.M. Verschuuren |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-02-01
|
Series: | JHLT Open |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2950133425000059 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Proteomics profiling of inflammatory responses to elexacaftor/tezacaftor/ivacaftor in cystic fibrosis
by: Hazel Ozuna, et al.
Published: (2025-01-01) -
Impact of elexacaftor-tezacaftor-ivacaftor in lung transplantation for cystic fibrosis in the United States
by: Tahuanty A. Pena, MD, MS, et al.
Published: (2025-02-01) -
Elexacaftor/tezacaftor/ivacaftor and inflammation in children and adolescents with cystic fibrosis: a retrospective dual-center cohort study
by: Angela Pepe, et al.
Published: (2025-02-01) -
The complexities of elexacaftor/tezacaftor/ivacaftor therapeutic drug monitoring in a person with cystic fibrosis and Mycobacterium abscessus pulmonary disease
by: Claire Y Mou, et al.
Published: (2025-12-01) -
Impact of elexacaftor/tezacaftor/ivacaftor (ETI) on the prescription refill rate (PRR) for inhaled medications in people with CF: an Italian multicenter analysis
by: Andrea Gramegna, et al.
Published: (2025-01-01)